5th IBDH Annual Symposium
Learning Objectives
- Review the common extraintestinal manifestations in IBD apply practical approach to screen and intervene as needed
- Appraise the currently available evidence of the effect of Cannabis and supplements in IBD
- Discuss the newly approved and soon to be approved biologic and non-biologic therapies for IBD, including the risks, efficacy and special considerations when utilizing these therapies
- Describe and understand the comparative efficacy of the currently available therapies and the rationale for optimal positioning of these options in IBD today
- Incorporate the concept of treat to target in IBD clinical practice and evaluate effectively how to incorporate into IBD management and goals of care
- Examine the current management of fibrostenotic Crohn’s complications and apply best up-to-date medical and surgical treatment strategies
- Apply up-to-date practice in managing dysplasia in IBD from detection to endoscopic and surgical intervention
- Identify the most promising therapies including antibodies and small molecules in late-stage clinical development, with an emphasis on immunological targets and pharmacological properties
Hourly Schedule
Hourly Schedule
- -
- Approach to Managing Common IBD Extraintestinal Manifestations
-
Speakers:
Bincy Abraham-- MD
- -
- Application of the Treat-To-Target Concept in Clinical Practice
-
Speakers:
Anita Afzali-- MD-- MPH-- MHCM
- -
- Comparative efficacy & positioning of IBD therapies today
-
Speakers:
Mark Osterman-- MD
- -
- Managing Fibrostenotic Crohn's Disease Complications
-
Speakers:
Florian Rieder-- MD
- -
- Cannabis & Alternative Therapy in IBD: Good, Bad or Ugly
-
Speakers:
Ghassan Wahbeh-- MD
- -
- Approach to managing Dysplasia in IBD
-
Speakers:
Mitra Barahimi-- MD
- -
- Promising Pathways and Upcoming Agents in IBD
-
Speakers:
Brian Feagan-- MD-- MSc
Bincy Abraham-- MD
Director, Fondren IBD Program, Director, Gastroenterology Fellowship Program Underwood Center for Digestive Disorders, Houston Methodist Hospital
Bincy P Abraham, MD, MS, AGAF, FACG is the Distinguished Professor and Director of the Fondren Inflammatory Bowel Disease Program at the Underwood Digestive Diseases Center of Houston Methodist Hospital. She is also the Program Director for the Gastroenterology Fellowship at Houston Methodist Hospital.
Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation (CCF) at Cedars-Sinai Medical Center in Los Angeles, California. After fellowship, she joined as faculty as assistant professor of medicine in the section of Gastroenterology and Hepatology at Baylor College of Medicine where she served as director of the Baylor Clinic Inflammatory Bowel Disease Center for over 5 years before her move to Houston Methodist Hospital. She is board-certified in Internal medicine and Gastroenterology.
Her particular interest in inflammatory bowel disease includes the transition of adolescent IBD patients from pediatric to adult care as well as women’s issues and pregnancy in IBD. She chairs the Southern Regional Chapter of the CCF Medical Advisory Committee, has served as president of the Texas Gulf Coast Gastroenterology Society, co-directed the Texas Society of Gastroenterology & Endoscopy Annual meeting, is involved in national committees for American College of Gastroenterology (ACG), a member of American Gastroenterology Association (AGA), and Crohn's and Colitis Foundation.
Anita Afzali-- MD-- MPH-- MHCM
Professor of Medicine in the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System
Dr. Anita Afzali is a Professor of Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. She is also the Associate Chief Medical Officer of the UC Health System. She received her medical degree and then completed Internal Medicine residency and gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and graduated with a Masters in Public Health from The University of Washington. She then later obtained another Masters In Healthcare Management (MHCM) from Harvard T.H. Chan School of Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty.
While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics. After Seattle, Dr. Afzali moved to Columbus, OH to be the Medical Director of The OSU IBD Center and the Vice Chair of Clinical Operations of Gastroenterology at The Ohio State University.
Recently, she has transitioned to the University of Cincinnati where she serves as the Executive Vice Chair of the Department of Internal Medicine. Her research interests include drug study design, investigational drug trials, and clinical outcomes. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Chair of the American College of Gastroenterology (ACG) Educational Affairs Committee and Vice Chair of Publications Committee for the World Gastroenterology Organization (WGO).
Mark Osterman-- MD
Associate Professor of Medicine
Mark Osterman, MD, MSCE is an Associate Professor of Medicine at the University of Pennsylvania Perelman School of Medicine where he serves as the Associate Director of IBD Research for the Penn Inflammatory Bowel Disease Center. He has been heavily involved in clinical research in inflammatory bowel disease, with a focus on clinical trials of novel therapies, optimization and safety of medical therapies using observational studies, therapeutic drug monitoring of immunosuppressant medications, and mucosal healing.
He has been lead PI or a steering committee member of a number of multi-center clinical trials. He is one of the nation’s pioneers of the study and use of proactive therapeutic drug monitoring for biologic therapy in IBD. His work has been funded by the AGA, NIH, CCF, pharmaceutical industries, and private philanthropy. Dr. Osterman has recently served as Chair of the Chapter Medical Advisory Committee for the CCF Philadelphia Chapter, for which he is also a board member.
Florian Rieder-- MD
Vice Department Chair in Gastroenterology, Hepatology & Nutrition and Co-Section Director in Inflammatory Bowel Diseases (IBD) at the Cleveland Clinic
Dr. Florian Rieder is Vice Department Chair in Gastroenterology, Hepatology & Nutrition and Co-Section Director in Inflammatory Bowel Diseases (IBD) at the Cleveland Clinic. His work has been acknowledged through national and international leadership roles in clinical guidelines and scientific initiatives. The Rieder lab is internationally recognized for its work on intestinal fibrosis. #WeTheFibrosisLab
He has published more than 60 articles and book chapters and serves on multiple committees, speakers’ panels, editorial boards, and steering committees. Dr. Rieder received multiple awards, including the Fellowship Award of the Crohn’s and Colitis Foundation (CCF), the best abstract award of the American Gastroenterology Association (AGA) and the Crohn’s and Colitis Foundation (CCF), the best poster award of the United European Gastroenterology Federation (UEG), three consecutive Excellence in Teaching Awards for exceptional teaching achievements at the Cleveland Clinic and three NIH awards (T32, P30 Pilot and K08).
Dr. Rieder loves to travel with his family.
Ghassan Wahbeh-- MD
Director of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations.
Ghassan Wahbeh, MD, is the Director of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with IBD, including advanced therapeutics and perioperative IBD management. He leads the Intestinal Ultrasound (IUS) Program at Seattle Children's.
Dr. Wahbeh's research interests include novel therapeutics for pediatric IBD, advanced disease monitoring towards mucosal healing, clinical standard work in managing severe ulcerative colitis and complicated Crohn’s disease including fistulizing and stricturing phenotypes, and navigating IBD surgical options. He is actively involved in translational IBD research at Seattle Children's Hospital.
Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training and fellow physician specialty, and advanced IBD specialty training.
He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohn’s & Colitis Foundation service award. Dr. Wahbeh enjoys playing soccer, skiing, and paddle-boarding with his wife and kids.
Dr. Ghassan Wahbeh is a co-founder of IBDHorizons
@PedsIBD_Wahbeh
Mitra Barahimi-- MD
Assistant Professor of Medicine at University of Washington
Dr. Barahimi is an assistant professor of medicine at the University of Washington with expertise in inflammatory bowel diseases (IBD). She earned her bachelor’s degree and MD at the University of Washington. She went on to complete her residency in internal medicine and fellowship in gastroenterology at the University of Washington.
In her clinical practice, Dr. Barahimi exclusively cares for patients with IBD. She is the principal investigator of IBD QORUS, a national quality improvement project that aims to improve the quality of care for patients with inflammatory bowel disease. She is also involved in clinical trials for new investigational therapies for inflammatory bowel disease. She is a member of the Crohn’s Colitis Foundation (CCF), American Gastroenterology Association (AGA), American College of Gastroenterology (ACG), and American Society of Gastrointestinal Endoscopy (ASGE).
Brian Feagan-- MD-- MSc
Professor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc
Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Inflammatory Bowel Diseases (IBD), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in IBD. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).
Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology (ACG), the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation (CCF) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored numerous articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).
Hourly Schedule
Hourly Schedule
- -
- Approach to Managing Common IBD Extraintestinal Manifestations
-
Speakers:
Bincy Abraham-- MD
- -
- Application of the Treat-To-Target Concept in Clinical Practice
-
Speakers:
Anita Afzali-- MD-- MPH-- MHCM
- -
- Comparative efficacy & positioning of IBD therapies today
-
Speakers:
Mark Osterman-- MD
- -
- Managing Fibrostenotic Crohn's Disease Complications
-
Speakers:
Florian Rieder-- MD
- -
- Cannabis & Alternative Therapy in IBD: Good, Bad or Ugly
-
Speakers:
Ghassan Wahbeh-- MD
- -
- Approach to managing Dysplasia in IBD
-
Speakers:
Mitra Barahimi-- MD
- -
- Promising Pathways and Upcoming Agents in IBD
-
Speakers:
Brian Feagan-- MD-- MSc
Bincy Abraham-- MD
Director, Fondren IBD Program, Director, Gastroenterology Fellowship Program Underwood Center for Digestive Disorders, Houston Methodist Hospital
Bincy P Abraham, MD, MS, AGAF, FACG is the Distinguished Professor and Director of the Fondren Inflammatory Bowel Disease Program at the Underwood Digestive Diseases Center of Houston Methodist Hospital. She is also the Program Director for the Gastroenterology Fellowship at Houston Methodist Hospital.
Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation (CCF) at Cedars-Sinai Medical Center in Los Angeles, California. After fellowship, she joined as faculty as assistant professor of medicine in the section of Gastroenterology and Hepatology at Baylor College of Medicine where she served as director of the Baylor Clinic Inflammatory Bowel Disease Center for over 5 years before her move to Houston Methodist Hospital. She is board-certified in Internal medicine and Gastroenterology.
Her particular interest in inflammatory bowel disease includes the transition of adolescent IBD patients from pediatric to adult care as well as women’s issues and pregnancy in IBD. She chairs the Southern Regional Chapter of the CCF Medical Advisory Committee, has served as president of the Texas Gulf Coast Gastroenterology Society, co-directed the Texas Society of Gastroenterology & Endoscopy Annual meeting, is involved in national committees for American College of Gastroenterology (ACG), a member of American Gastroenterology Association (AGA), and Crohn's and Colitis Foundation.
Anita Afzali-- MD-- MPH-- MHCM
Professor of Medicine in the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System
Dr. Anita Afzali is a Professor of Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. She is also the Associate Chief Medical Officer of the UC Health System. She received her medical degree and then completed Internal Medicine residency and gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and graduated with a Masters in Public Health from The University of Washington. She then later obtained another Masters In Healthcare Management (MHCM) from Harvard T.H. Chan School of Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty.
While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics. After Seattle, Dr. Afzali moved to Columbus, OH to be the Medical Director of The OSU IBD Center and the Vice Chair of Clinical Operations of Gastroenterology at The Ohio State University.
Recently, she has transitioned to the University of Cincinnati where she serves as the Executive Vice Chair of the Department of Internal Medicine. Her research interests include drug study design, investigational drug trials, and clinical outcomes. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Chair of the American College of Gastroenterology (ACG) Educational Affairs Committee and Vice Chair of Publications Committee for the World Gastroenterology Organization (WGO).
Mark Osterman-- MD
Associate Professor of Medicine
Mark Osterman, MD, MSCE is an Associate Professor of Medicine at the University of Pennsylvania Perelman School of Medicine where he serves as the Associate Director of IBD Research for the Penn Inflammatory Bowel Disease Center. He has been heavily involved in clinical research in inflammatory bowel disease, with a focus on clinical trials of novel therapies, optimization and safety of medical therapies using observational studies, therapeutic drug monitoring of immunosuppressant medications, and mucosal healing.
He has been lead PI or a steering committee member of a number of multi-center clinical trials. He is one of the nation’s pioneers of the study and use of proactive therapeutic drug monitoring for biologic therapy in IBD. His work has been funded by the AGA, NIH, CCF, pharmaceutical industries, and private philanthropy. Dr. Osterman has recently served as Chair of the Chapter Medical Advisory Committee for the CCF Philadelphia Chapter, for which he is also a board member.
Florian Rieder-- MD
Vice Department Chair in Gastroenterology, Hepatology & Nutrition and Co-Section Director in Inflammatory Bowel Diseases (IBD) at the Cleveland Clinic
Dr. Florian Rieder is Vice Department Chair in Gastroenterology, Hepatology & Nutrition and Co-Section Director in Inflammatory Bowel Diseases (IBD) at the Cleveland Clinic. His work has been acknowledged through national and international leadership roles in clinical guidelines and scientific initiatives. The Rieder lab is internationally recognized for its work on intestinal fibrosis. #WeTheFibrosisLab
He has published more than 60 articles and book chapters and serves on multiple committees, speakers’ panels, editorial boards, and steering committees. Dr. Rieder received multiple awards, including the Fellowship Award of the Crohn’s and Colitis Foundation (CCF), the best abstract award of the American Gastroenterology Association (AGA) and the Crohn’s and Colitis Foundation (CCF), the best poster award of the United European Gastroenterology Federation (UEG), three consecutive Excellence in Teaching Awards for exceptional teaching achievements at the Cleveland Clinic and three NIH awards (T32, P30 Pilot and K08).
Dr. Rieder loves to travel with his family.
Ghassan Wahbeh-- MD
Director of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations.
Ghassan Wahbeh, MD, is the Director of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with IBD, including advanced therapeutics and perioperative IBD management. He leads the Intestinal Ultrasound (IUS) Program at Seattle Children's.
Dr. Wahbeh's research interests include novel therapeutics for pediatric IBD, advanced disease monitoring towards mucosal healing, clinical standard work in managing severe ulcerative colitis and complicated Crohn’s disease including fistulizing and stricturing phenotypes, and navigating IBD surgical options. He is actively involved in translational IBD research at Seattle Children's Hospital.
Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training and fellow physician specialty, and advanced IBD specialty training.
He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohn’s & Colitis Foundation service award. Dr. Wahbeh enjoys playing soccer, skiing, and paddle-boarding with his wife and kids.
Dr. Ghassan Wahbeh is a co-founder of IBDHorizons
@PedsIBD_Wahbeh
Mitra Barahimi-- MD
Assistant Professor of Medicine at University of Washington
Dr. Barahimi is an assistant professor of medicine at the University of Washington with expertise in inflammatory bowel diseases (IBD). She earned her bachelor’s degree and MD at the University of Washington. She went on to complete her residency in internal medicine and fellowship in gastroenterology at the University of Washington.
In her clinical practice, Dr. Barahimi exclusively cares for patients with IBD. She is the principal investigator of IBD QORUS, a national quality improvement project that aims to improve the quality of care for patients with inflammatory bowel disease. She is also involved in clinical trials for new investigational therapies for inflammatory bowel disease. She is a member of the Crohn’s Colitis Foundation (CCF), American Gastroenterology Association (AGA), American College of Gastroenterology (ACG), and American Society of Gastrointestinal Endoscopy (ASGE).
Brian Feagan-- MD-- MSc
Professor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc
Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Inflammatory Bowel Diseases (IBD), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in IBD. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).
Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology (ACG), the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation (CCF) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored numerous articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).
;
